Plasma and cerebrospinal fluid therapeutic drug monitoring of ceftolozane and tazobactam during treatment of multidrug-resistant *Pseudomonas aeruginosa* meningitis

Erin K. McCreary¹, Karin E. Byers¹, Carolyn Fernandes¹, Ellen G. Kline¹, David P. Nicolau², Ryan K. Shields¹

1. Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA, USA
2. Center for Anti-Infective Research and Development, Hartford, CT, USA

**Corresponding Author:**
Ryan K. Shields, PharmD, MS
Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
Email: shieldsrk@upmc.edu
Fax: 412-648-6399
Telephone: 412-864-3745

**Alternate Corresponding Author:**
Erin K. McCreary, PharmD, BCPS, BCIDP
Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
Email: mccrearye3@upmc.edu
Fax: 412-648-6399
Telephone: 484-515-9589

© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Abstract:

We report a case of multidrug-resistant *Pseudomonas aeruginosa* meningitis treated with ceftolozane-tazobactam with concomitant therapeutic drug monitoring of plasma and cerebral spinal fluid. The data suggest ceftolozane-tazobactam may be an option for select central nervous system infections; however, treatment decisions should be interpreted on a case-by-case basis.

Keywords: gram-negative, central nervous system, difficult-to-treat, beta-lactamase inhibitor
BACKGROUND

Multidrug-resistant (MDR) gram-negative bacteria associated with difficult-to-treat phenotypes are a major challenge in clinical practice and associated with high mortality.\(^1\)^\(^2\) Central nervous system (CNS) infections pose an additional layer of complexity for clinicians due to low and possibly inadequate antimicrobial concentrations obtained in cerebral spinal fluid (CSF) at standard dosing as well as the poorly described distribution of drug into other spaces within the CNS.\(^3\) While recently developed β-lactam/β-lactamase inhibitors (BLBLI) including ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam have demonstrated promise in the treatment of pneumonia, urinary tract infections, intraabdominal infections, and bloodstream infections due to carbapenem-resistant Enterobacteriaceae\(^4\)^\(^5\) and Pseudomonas aeruginosa\(^6\)^\(^8\), the real-world experience for use of these agents in CNS infections is limited.\(^9\)^\(^\text{19}\) Here, we describe a case of MDR P. aeruginosa meningitis treated with ceftolozane-tazobactam with concomitant therapeutic drug monitoring (TDM).

CASE

A 39-year-old male presented to a referring facility as a level 1 trauma following an unhelmeted motorcycle crash resulting in a right frontotemporal contusion with subarachnoid hemorrhage and subdural hematoma. The patient was emergently taken to the operating room (OR) for a right subdural hematoma evacuation and frontotemporal decompressive hemicraniectomy. Upon arrival to our facility the next day, repeat imaging demonstrated stable multiple compartment intracranial hemorrhage. On hospital day 10, the patient became tachycardic and had new-onset leukocytosis. He was subsequently taken to the OR for right frontotemporoparietal wound washout and revision. Operative cultures grew Escherichia coli, Serratia marcescens, methicillin-susceptible Staphylococcus aureus, P.
*P. aeruginosa*, and *Bacteroides* spp., which were treated with meropenem 2g IV every 8h infused over 30 minutes.

The patient had subsequent wound debridement on hospital day 19 and wound closure with tensor fascia dural graft placement on hospital day 21. On hospital day 37, while on continued meropenem treatment, the patient developed new fevers, worsening leukocytosis, and tachycardia. Corresponding blood cultures were negative; however, CSF cultures grew MDR *P. aeruginosa* (*Table*). In response, meropenem was discontinued in favor of ceftolozane-tazobactam 3g (2g ceftolozane, 1g tazobactam) IV every 8 hours infused over 1 hour (MIC = 1µg/mL), ciprofloxacin 400mg IV every 8 hours (MIC ≤ 1µg/mL), and metronidazole 500mg IV every 8 hours. In addition, tobramycin 10mg intraventricular (MIC ≤ 1µg/mL) was administered once on hospital day 38 followed by 5mg every 24 hours on days 40-43. The patient demonstrated rapid clinical improvement with resolution of fever, leukocytosis, and hemodynamic stability and was subsequently discharged to an inpatient rehabilitation unit on hospital day 55. He completed a 6-week course of ceftolozane-tazobactam, ciprofloxacin, and metronidazole with complete wound and flap healing and resolution of meningitis. The patient remained infection-free through one-year post treatment completion.

**PHARMACOKINETIC ANALYSIS**

Steady-state plasma and CSF ceftolozane and tazobactam concentrations were measured on hospital days 42 and 44 (*Table*). CSF was drawn from an external ventricular drain (EVD). Whole blood samples were immediately centrifuged; plasma and CSF were stored at -80°C until analysis by validated high-performance liquid chromatography (HPLC) as described previously. At the time of sampling, the patient weighed 70 kilograms and had an estimated glomerular filtration rate of 119 mL/min/1.73m². The patient was in the neurosurgical intensive care unit (ICU) but was not intubated or sedated at the time of sampling.
After the patient’s 8th dose of ceftolozane-tazobactam, the calculated maximum (\(C_{\text{max}}\)) and minimum (\(C_{\text{min}}\)) plasma concentrations of ceftolozane were 72.7\(\mu\)g/mL and 9.8\(\mu\)g/mL, respectively. Ceftolozane half-life, \(V_d\), and total body clearance from plasma were 2.42h, 35.9L, and 10.28L/h, respectively. Corresponding values for tazobactam were 23\(\mu\)g/mL (\(C_{\text{max}}\)), 0.3\(\mu\)g/mL (\(C_{\text{min}}\)), 1.13h (\(t_{1/2}\)), 32.6L (\(V_d\)), and 19.9L/h (CL). Two hours after the start of the next dose of ceftolozane-tazobactam, simultaneous samples from plasma and CSF showed ceftolozane concentrations of 55.75\(\mu\)g/mL and 4.13\(\mu\)g/mL, respectively. Total and free drug (assuming 20% plasma protein binding) penetration ratios were 0.074 and 0.093, respectively. Corresponding tazobactam concentrations from plasma and CSF were 11.44\(\mu\)g/mL and <0.4\(\mu\)g/mL, respectively. Repeat plasma and CSF samples drawn one hour after the start of 15th dose showed ceftolozane concentrations of 81.61\(\mu\)g/mL and 6.98\(\mu\)g/mL, respectively; calculated penetration ratios using total and free drug concentrations were 0.085 and 0.107. At the same time point, the tazobactam concentration in plasma was 24.30\(\mu\)g/mL and in CSF was 0.82\(\mu\)g/mL.

**DISCUSSION**

We present a case of MDR *P. aeruginosa* meningitis treated with ceftolozane-tazobactam where concomitant TDM was performed in both plasma and CSF. The confluence of drug-resistant bacteria causing a life-threatening infection at a body site impermeable to many antibiotics represents a serious challenge to clinicians. For these reasons, we opted to use combination therapy for this patient, which confounds the interpretation of any specific therapy on the patient outcome. It is unclear if a shorter duration of therapy or treatment with monotherapy would have resulted in a similar outcome. Nevertheless, we have shown that therapeutic concentrations of ceftolozane were achieved in the CSF with standard doses that may have contributed to clinical cure for the patient.

Our experience builds upon limited clinical data describing use of ceftolozane-tazobactam for the treatment of meningitis and is similar to a previously published a case report of MDR
P. aeruginosa otogenous meningitis treated with ceftolozane-tazobactam in combination with IV fosfomycin, rifampin, and appropriate source control. Another case report of ceftolozane-tazobactam for MDR P. aeruginosa meningitis is a 22-year-old male who received monotherapy for 11 days with initial microbiological cure and a favorable clinical outcome, but had recurrence of infection by day 28. Winans and colleagues described a 36-year-old male who received ceftolozane-tazobactam 9 g continuous infusion for treatment of carbapenem-resistant P. aeruginosa meningitis and measured ceftolozane concentrations in the CSF, which were 83% of those in the serum. There are also limited data to suggest ceftazidime-avibactam may be a viable option for treatment of meningitis. In our case, ceftolozane-tazobactam was chosen based on our local susceptibility rates that demonstrate a higher likelihood of activity in the empiric setting and was continued after susceptibility testing confirmed a lower MIC than ceftazidime-avibactam against the MDR P. aeruginosa isolate.

While the pharmacokinetics of antibiotics in the CSF are poorly defined, the half-life of cephalosporins may be prolonged and vary based on rates of CSF production, EVD drainage pressure scale and alternations, volume of CSF space including ventricle size, and integrity of the blood-brain barrier. Since drug entry into the CSF is delayed compared to other body fluids and compartments, through a phenomenon known as system hysteresis, it is likely that the ratio of drug in CSF to plasma increases from the time of initiation of the drug infusion. Therefore, the ratio of the AUC of CSF to serum at steady state (AUC_{CSF}/AUC_{SS}) is the most accurate means of characterizing drug penetration into the CSF. The AUC_{CSF}/AUC_{SS} for traditional cephalosporins ranges from 0.007 - 0.17 and is dependent upon the degree of meningeal inflammation and other patient-specific factors.

Recently, Sime and colleagues evaluated 10 critically ill patients with an indwelling EVD and found a mean free AUC_{CSF}/AUC_{plasma} ratio of 0.2 after a single 3g dose of ceftolozane/tazobactam. Notably fAUC ratios were highly variable (standard deviation of 0.2) and lower among patients without CNS infections (mean penetration ratio of 0.0685 ±
0.0156). We were unable to define the AUC_{CSF} for our patient due to limited EVD drainage; however, our point estimates are similar to those described for cephalosporins used commonly in the treatment of meningitis, even in patients with uninflamed meninges.³ It should be noted that at the time of sampling, our patient had been hospitalized for 6 weeks and demonstrated stable encephalomalacia on imaging. We anticipate that ceftolozane penetration ratios may be even higher in the setting of acute meningeal inflammation compared to those observed here, which are consistent with the findings of Sime and colleagues.¹⁸

The ceftolozane-tazobactam MIC was 1 µg/mL against the *P. aeruginosa* strain in this case and thus, pharmacodynamic targets of 100% ft>MIC and 100% ft>4x MIC were achieved in the plasma. These targets are useful predictors of clinical efficacy and suppression of resistance, respectively.²³ A plasma level drawn 4 hours after the start of the ceftolozane infusion in our patient was 29.45 µg/mL; if 9-11% of unbound ceftolozane penetrated into the CNS as suggested by our sampling, then at least 50% ft>MIC was achieved in the CNS. The efficacy target for ceftolozane and *P. aeruginosa* meningitis has not been described. In a non-meningitis murine model, a ft>MIC of 31.5% ± 3.9% achieved 1-log₁₀ bacterial kill against wild-type *P. aeruginosa*, a threshold lower than other cephalosporins that is associated with more rapid killing of *P. aeruginosa*.²⁴

It is important to note that while the CSF concentration is the closest approximation of drug concentration in the extracellular space of the CNS, and is therefore used in clinical practice as a surrogate of total drug exposure in the CNS, it has been demonstrated that antibiotic levels in the CSF vary significantly and do not predict clinical cure.²⁵ Moreover, it is unknown how drug concentrations in various compartments of the nervous tissue (e.g., interstitial space, meningeal layers) are related to CSF concentrations at any point in time. Indeed, biopsied animal brain tissue has demonstrated antimicrobial concentrations in brain parenchyma 10-20% of that in the serum despite undetectable CSF levels.²⁶
Our data should be interpreted cautiously when considering ceftolozane-tazobactam for non-
P. aeruginosa CNS infections. The concentration threshold of free tazobactam when combined with ceftolozane for efficacy in CTX-15-producing Escherichia coli and Klebsiella pneumoniae infections has been described as half the value of the ceftolozane-tazobactam MIC (i.e., a tazobactam concentration threshold of 0.5µg/mL for an isolate with an MIC of 1µg/mL) for 77% of the dosing interval to achieve a change in log_{10} CFU from baseline. Based on our patient’s peak tazobactam concentration in CSF and previously published pharmacokinetic data regarding tazobactam and CSF, ceftolozane-tazobactam is unlikely to achieve the tazobactam pharmacodynamic target necessary for 1-log_{10} bacterial kill against extended-spectrum β-lactamase (ESBL)-producing Enterobacterales in the CSF.

CONCLUSION

This is the first described case of steady-state plasma and CSF ceftolozane and tazobactam concentrations measured during the treatment of MDR P. aeruginosa bacterial meningitis. The data suggest that ceftolozane pharmacodynamic targets in both the CSF and plasma can be achieved using a regimen of 3g IV q 8h; however, these data should be interpreted on a case by case basis. Further investigations are needed to make any distinction between specific β-lactam/β-lactamase inhibitor combinations for meningitis, monotherapy versus combination therapy considerations, and to determine the optimal duration of treatment for MDR P. aeruginosa meningitis.
Table. Ceftolozane and tazobactam plasma and CSF levels measured during treatment of multidrug resistant *P. aeruginosa* meningitis

| Hospital day | Time | Action | Total Ceftolozane Concentration (µg/mL) | Total Tazobactam Concentration (µg/mL) |
|--------------|------|--------|----------------------------------------|----------------------------------------|
| 41           | 2344 | 2g ceftolozane, 1g tazobactam (dose #7) administered (1h infusion) | NA | NA |
| 42           | 0750 | Plasma sample drawn | 8.46 | 1.4 |
| 42           | 0801 | 2g ceftolozane, 1g tazobactam (dose #8) (1h infusion) | NA | NA |
| 42           | 1000 | Plasma sample drawn | 54.81 | 12.58 |
| 42           | 1210 | Plasma sample drawn | 29.45 | 3.34 |
| 42           | 1546 | Plasma sample drawn | 8.76 | 0.59 |
| 42           | 1625 | 2g ceftolozane, 1g tazobactam (dose #9) (1h infusion) | NA | NA |
| 42           | 1830 | Plasma sample drawn | 55.75 | 11.44 |
| 42           | 1830 | CSF sample drawn | 4.13 | BDL |
| 44           | 0755 | 2g ceftolozane, 1g tazobactam (dose #15) (1h infusion) | NA | NA |
| 44           | 0905 | Plasma sample drawn | 81.61 | 24.30 |
| 44           | 0905 | CSF sample drawn | 6.98 | 0.82 |

BDL=below detectable limit of 0.4µg/mL; CSF = cerebral spinal fluid; g = gram; h = hour; NA = no sample collected

*P. aeruginosa* isolate was resistant to aztreonam (MIC >16 µg/mL), ceftazidime (MIC >16 µg/mL), cefepime (MIC >16 µg/mL), piperacillin/tazobactam (MIC >64 µg/mL), and meropenem (MIC >8 µg/mL), and susceptible to ciprofloxacin (MIC ≤ 1 µg/mL), gentamicin (MIC ≤ 1 µg/mL), tobramycin (MIC ≤ 1 µg/mL), ceftolozane/tazobactam (MIC = 1 µg/mL), and ceftazidine/avibactam (MIC = 3 µg/mL).
**Patient consent statement:** The patient’s written consent was confirmed prior to collection of plasma and CSF samples. All procedures followed were in accordance with the ethical standards of the Helsinki Declaration. This work has been approved by the University of Pittsburgh Institutional Review Board.

**Acknowledgements:** The authors would like to thank Kailey Hughes for facilitating sample collection in this patient, Thomas Lodise for this thoughtful review of this manuscript, and Christina Sutherland, B.S. and the Hartford Hospital Center for Anti-Infective Research and Development for determination of ceftolozane and tazobactam concentrations.

**Funding:** This was unfunded, original research. No authors received any research or grant support for the work presented.

**Conflicts of Interest:** EM has served on advisory boards for Entasis, Merck, AbbVie, Shionogi, and Summit. R.K.S. has received grant support from Accelerate Diagnostics, Achaogen, Allergan, Merck, Melinta, Roche, Shionogi, Tetraphase, and VenatoRx, and the National Institutes of Health under award numbers K08AI114883 and R03AI144636, has served on advisory boards for Accelerate Diagnostics, Achaogen, Allergan, Entasis, Merck, Nabriva, Shionogi, Summit and VenatoRx, and has received speaking honorarium from Allergan, Menarini, Pfizer, and T2Biosystems. No other authors have any conflicts of interest to disclose.
References

1. Kadri SS, Adjemian J, Lai YL, et al. Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018;67(12):1803-1814.

2. Huh K, Chung DR, Ha YE, et al. Impact of difficult-to-treat resistance in gram-negative bacteremia on mortality: retrospective analysis of nationwide surveillance data. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020.

3. Nau R, Sorgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clinical microbiology reviews. 2010;23(4):858-883.

4. Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia. Antimicrobial agents and chemotherapy. 2017;61(8).

5. Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. Infectious diseases and therapy. 2018;7(4):439-455.

6. Motsch J, Murta de Oliveira C, Stus V, et al. RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2019.

7. Pogue JM, Kaye KS, Veve MP, et al. Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas Aeruginosa. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2019.

8. Jorgensen SCJ, Trinh TD, Zasowski EJ, et al. Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections. Open forum infectious diseases. 2019;6(12):ofz522.

9. Iosifidis E, Chorafa E, Agakidou E, et al. Use of Ceftazidime-avibactam for the Treatment of Extensively drug-resistant or Pan drug-resistant Klebsiella pneumoniae in Neonates and Children <5 Years of Age. The Pediatric infectious disease journal. 2019;38(8):812-815.

10. Gofman N, To K, Whitman M, Garcia-Morales E. Successful treatment of ventriculitis caused by Pseudomonas aeruginosa and carbapenem-resistant Klebsiella pneumoniae with i.v. ceftazidime-avibactam and intrathecal amikacin. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2018;75(13):953-957.

11. Rodriguez-Nunez O, Ripa M, Morata L, et al. Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa. Journal of global antimicrobial resistance. 2018;15:136-139.

12. Holyk A, Belden V, Lee JJ, et al. Ceftazidime/avibactam use for carbapenem-resistant Klebsiella pneumoniae meningitis: a case report. The Journal of antimicrobial chemotherapy. 2018;73(1):254-256.

13. Xipell M, Bodro M, Marco F, Losno RA, Cardozo C, Soriano A. Clinical experience with ceftazidime/avibactam in patients with severe infections, including meningitis and lung abscesses, caused by extensively drug-resistant Pseudomonas aeruginosa. International journal of antimicrobial agents. 2017;49(2):266-268.

14. Frattari A, Savini V, Polilli E, et al. Ceftolozane-tazobactam and Fosfomycin for rescue treatment of otogenous meningitis caused by XDR Pseudomonas aeruginosa: Case report and review of the literature. IDCases. 2018;14:e00451.
15. Samuel S EN, Rojas L, et al. Ceftazidime-avibactam for the treatment of post-neurosurgical meningitis caused by a Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae. *Open forum infectious diseases*. 2016;3:1182.
16. Dinh A, Wyposz B, Kerneis S, et al. Use of ceftolozane/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa. *International journal of antimicrobial agents*. 2017;49(6):782-783.
17. Yasmin M HJ, Marshall S, et al. Using Therapeutic Drug Monitoring to Treat KPC-Producing Klebsiella pneumoniae Central Nervous System Infection With Ceftazidime/Avibactam. *Open Forum Infect Dis*. 2020.
18. Sime FB, Lassig-Smith M, Starr T, et al. Cerebrospinal fluid penetration of ceftolozane/tazobactam in critically ill patients with an indwelling external ventricular drain. *Antimicrobial Agents and Chemotherapy*. 2020;AAC.01698-01620.
19. Winans SA, Guerrero-Wooley RL, Park SH, Hino G, Jr., Forland SC. Continuous infusion of ceftolozane-tazobactam resulted in high cerebrospinal fluid concentrations of ceftolozane in a patient with multidrug-resistant Pseudomonas aeruginosa meningitis. *Infection*. 2020.
20. Sutherland CA, Nicolau DP. Development of an HPLC Method for the Determination of Ceftolozane/Tazobactam in Biological and Aqueous Matrixes. *Journal of chromatographic science*. 2016;54(6):1037-1040.
21. Nau R, Zysk G, Thiel A, Prange HW. Pharmacokinetic quantification of the exchange of drugs between blood and cerebrospinal fluid in man. *European journal of clinical pharmacology*. 1993;45(5):469-475.
22. Lodise TP, Jr., Rhoney DH, Tam VH, McKinnon PS, Drusano GL. Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies. *Diagnostic microbiology and infectious disease*. 2006;54(3):223-230.
23. Tam VH, Chang KT, Zhou J, et al. Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria. *J Antimicrob Chemother*. 2017;72(5):1421-1428.
24. Craig WA, Andes DR. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum beta-lactamases, in the thighs of neutropenic mice. *Antimicrobial agents and chemotherapy*. 2013;57(4):1577-1582.
25. Beach JE, Perrott J, Turgeon RD, Ensom MHH. Penetration of Vancomycin into the Cerebrospinal Fluid: A Systematic Review. *Clinical pharmacokinetics*. 2017;56(12):1479-1490.
26. Kethireddy S, Andes D. CNS pharmacokinetics of antifungal agents. *Expert opinion on drug metabolism & toxicology*. 2007;3(4):573-581.
27. Vanscoy B, Mendes RE, McCauley J, et al. Pharmacological basis of beta-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane. *Antimicrobial agents and chemotherapy*. 2013;57(12):5924-5930.
28. Nau R, Kinzig-Schippers M, Sorgel F, et al. Kinetics of piperacillin and tazobactam in ventricular cerebrospinal fluid of hydrocephalic patients. *Antimicrobial agents and chemotherapy*. 1997;41(5):987-991.